Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AXL_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AXL_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/AXL_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AXL_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004887220 | Oral cavity | OSCC | homeostasis of number of cells | 152/7305 | 272/18723 | 1.08e-08 | 2.23e-07 | 152 |
GO:190121420 | Oral cavity | OSCC | regulation of neuron death | 174/7305 | 319/18723 | 1.09e-08 | 2.23e-07 | 174 |
GO:003158917 | Oral cavity | OSCC | cell-substrate adhesion | 193/7305 | 363/18723 | 2.48e-08 | 4.82e-07 | 193 |
GO:003410120 | Oral cavity | OSCC | erythrocyte homeostasis | 81/7305 | 129/18723 | 3.75e-08 | 7.06e-07 | 81 |
GO:003010016 | Oral cavity | OSCC | regulation of endocytosis | 121/7305 | 211/18723 | 4.74e-08 | 8.80e-07 | 121 |
GO:00310999 | Oral cavity | OSCC | regeneration | 114/7305 | 198/18723 | 8.54e-08 | 1.50e-06 | 114 |
GO:00703017 | Oral cavity | OSCC | cellular response to hydrogen peroxide | 63/7305 | 98/18723 | 3.51e-07 | 5.30e-06 | 63 |
GO:006145817 | Oral cavity | OSCC | reproductive system development | 217/7305 | 427/18723 | 3.75e-07 | 5.63e-06 | 217 |
GO:005140217 | Oral cavity | OSCC | neuron apoptotic process | 134/7305 | 246/18723 | 5.65e-07 | 8.19e-06 | 134 |
GO:003249617 | Oral cavity | OSCC | response to lipopolysaccharide | 178/7305 | 343/18723 | 7.27e-07 | 1.03e-05 | 178 |
GO:004860816 | Oral cavity | OSCC | reproductive structure development | 214/7305 | 424/18723 | 8.58e-07 | 1.18e-05 | 214 |
GO:004851116 | Oral cavity | OSCC | rhythmic process | 157/7305 | 298/18723 | 1.00e-06 | 1.36e-05 | 157 |
GO:00019594 | Oral cavity | OSCC | regulation of cytokine-mediated signaling pathway | 87/7305 | 150/18723 | 1.82e-06 | 2.35e-05 | 87 |
GO:00607594 | Oral cavity | OSCC | regulation of response to cytokine stimulus | 92/7305 | 162/18723 | 3.25e-06 | 3.90e-05 | 92 |
GO:004440920 | Oral cavity | OSCC | entry into host | 86/7305 | 151/18723 | 5.74e-06 | 6.37e-05 | 86 |
GO:003367418 | Oral cavity | OSCC | positive regulation of kinase activity | 228/7305 | 467/18723 | 8.31e-06 | 8.90e-05 | 228 |
GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
GO:007121615 | Oral cavity | OSCC | cellular response to biotic stimulus | 129/7305 | 246/18723 | 1.20e-05 | 1.23e-04 | 129 |
GO:000223717 | Oral cavity | OSCC | response to molecule of bacterial origin | 181/7305 | 363/18723 | 1.48e-05 | 1.49e-04 | 181 |
GO:004671820 | Oral cavity | OSCC | viral entry into host cell | 81/7305 | 144/18723 | 1.98e-05 | 1.89e-04 | 81 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AXL | SNV | Missense_Mutation | rs144824336 | c.1498N>A | p.Val500Met | p.V500M | P30530 | protein_coding | deleterious(0) | possibly_damaging(0.835) | TCGA-A7-A4SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
AXL | SNV | Missense_Mutation | rs756510536 | c.1906N>T | p.Arg636Trp | p.R636W | P30530 | protein_coding | deleterious(0.02) | benign(0.098) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AXL | SNV | Missense_Mutation | novel | c.1100N>G | p.Tyr367Cys | p.Y367C | P30530 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AXL | SNV | Missense_Mutation | rs374699228 | c.818N>T | p.Ala273Val | p.A273V | P30530 | protein_coding | tolerated(0.27) | benign(0.005) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
AXL | SNV | Missense_Mutation | rs751738506 | c.883N>T | p.Arg295Trp | p.R295W | P30530 | protein_coding | tolerated(0.17) | possibly_damaging(0.88) | TCGA-D8-A27R-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD |
AXL | SNV | Missense_Mutation | | c.598A>G | p.Thr200Ala | p.T200A | P30530 | protein_coding | tolerated(0.13) | benign(0.054) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD |
AXL | insertion | Frame_Shift_Ins | rs778012871 | c.867_868insC | p.His292ProfsTer47 | p.H292Pfs*47 | P30530 | protein_coding | | | TCGA-BH-A1FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
AXL | insertion | Frame_Shift_Ins | rs778012871 | c.867_868insC | p.His292ProfsTer47 | p.H292Pfs*47 | P30530 | protein_coding | | | TCGA-E9-A1NI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
AXL | SNV | Missense_Mutation | novel | c.226N>A | p.Leu76Met | p.L76M | P30530 | protein_coding | deleterious(0.02) | possibly_damaging(0.744) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
AXL | SNV | Missense_Mutation | | c.1279N>T | p.Arg427Cys | p.R427C | P30530 | protein_coding | tolerated(0.06) | possibly_damaging(0.66) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | | DASATINIB | DASATINIB | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | | PF-562271 | PF-00562271 | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | 363894214 | SITRAVATINIB | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | 404859021 | | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | 363894135 | MERESTINIB | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | | XL999 | | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | | Gilteritinib | GILTERITINIB | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | 252827520 | DUBERMATINIB | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | | BI-505 | BI-505 | |